A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke
A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke
Sponsor: Chandler Regional Medical Center at Chandler AZ
This PHASE1/PHASE2 trial investigates Ischemic Stroke and is currently completed. Chandler Regional Medical Center at Chandler AZ leads this study, which shows 8 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — May 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chandler Regional Medical Center at Chandler AZ
- Mercy Gilbert Medical Center at AZ
- Stemedica Cell Technologies, Inc.
- UCI Medical Center
- University of California, San Diego
For direct contact, visit the study record on ClinicalTrials.gov .